“We are at the forefront of revolutionary advancements in cancer immunotherapy with our cutting-edge messenger ribonucleic acid (mRNA)-based vaccine. Our mission is to harness the power of the body’s immune system to target and eradicate cancer cells, offering new hope to patients and families worldwide.”
Jean-Pol Detiffe, Chief Strategy & Innovation Officer at OncoDNA and Co-founder of OncoRNA
OncoRNA, a game changerin Cancer RNA Therapy
Unlike traditional treatments, OncoRNA mRNA-based cancer vaccine takes a personalized approach, tailoring the immune response to the unique genetic profile of each patient’s cancer. By encoding specific tumor antigens into the mRNA, we empower the immune system to recognize and attack cancer cells with unprecedented precision and efficiency.
Faster, Easier and Affordable
OncoRNA technology is based on Synthetic DNA pool, a process much FASTER , AFFORDABLE and EASIER TO CONTROL compared to plasmids compared to living organisms
Personalized
RNA production is individualised as a pool (compared to concatenated) which provides higher homogeneity in yield of RNA production and in-vivo translation
Large production of neoantigens
Because there is no limitation in termes of neoantigens numbers, the patented technology enables the production of more than 100 neoantigens (vs. max 20/30 with Plasmids)
know-how
OncoRNA is a spin-out of OncoDNA, the European leader in theranostic and genomic services with renowned expertise of 10 years in precision oncology. Combined with OncoRNA's cutting-edge technology, this expertise allows rapid identification of neoantigen (by nucleotide sequence comparison) and tailored snmRNA pool manufacturing (synthetic DNA pool) ensuring patients to get the most personalized cancer vaccine in the shortest time.
TUMOR BIOPSY IS ANALYZED TO IDENTIFY DNA & RNA MUTATIONS
Block title
NEOANTIGEN IDENTIFICATION BY NUCLEOTIDE SEQUENCE COMPARISON
Block title
TAILORED SNMRNA POOL MANUFACTURING
Block title
“We have envisioned a novel approach for generating a pool of individualized and personalized RNAs within a single tube, free from neoantigen design constraints”
Christophe Van Huffel, Co-founder & CSO
3 WEEKS PRODUCTION PROCESS
OncoRNA’s innovative process allows rapid production of the targeted therapy in only 3 weeks. The biopsy is followed by a molecular profiling done by OncoDNA to identify key mutations. In the second week, custom RNA messengers are synthesized to target these specific mutations. By the third week, the synthesized RNA messengers are prepared accordingly to GMP. After the third week, the vaccine can be injected into the patient’s body, where it initiates a targeted immune response against the cancer cells. This streamlined approach holds immense promise for efficient and personalized cancer treatment.
